Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Study Overview

• Status: Recruiting
• Conditions: Relapsed or Refractory Multiple Myeloma
• Intervention / Treatment: Drug: Mitoxantrone Hydrochloride Liposome injection; Drug: Bortezomib for Injection; Drug: Dexamethasone Acetate Tablets

Detailed Description

This is a multicenter, open-label, phase I study aimed to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. In the study, 60 patients will be recruited into three dose groups. All patients will receive the treatment for the planned 8 cycles(28 days per cycle）until disease progression or unacceptable drug-related adverse events

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Na An; Phone Number: +86-010-63930582; Email: anna@mail.ecspc.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China
      • Recruiting
      • Beijing Chaoyang Hospital, Capital Medical University
      • Contact: Wenming Chen, Doctor; Phone Number: 13910107759; Email: 13910107759@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients fully understand and voluntarily participate in this study and sign informed consent;
2. Aged 18-75 years, without gender limitation;
3. Patients with relapsed or refractory multiple myeloma(confirmed by histologically or cytologically) who had received at least one prior line regular treatment;
4. Patients have at least one of the following conditions:（1）Serum M protein≥10g/L;（2）Urine M protein≥200 mg/24h; （3）Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥100mg /L
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;

6. Laboratory tests meet the following conditions:

   • Absolute neutrophil count (ANC) ≥1.5x10^9/L (No G-CSF treatment within 1 week prior to the laboratory test);
   • Platelet count ≥ 75x10^9/L (No platelet transfusion within 1 week prior to the laboratory test);
   • Total bilirubin ≤1.5upper limit of normal (ULN);
   • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN;
   • Creatinine clearance(Ccr) ≥30mL/min.
7. Females of childbearing potential must have a negative serum beta human chorionic gonadotrophin (β-hCG) pregnancy test result prior to enrollment and must agree to use an effective contraception method for the duration of the study treatment and 7 months after the last dose of study therapy.

8. Males patients and their partners must agree to use an effective contraceptive method for the duration of the study treatment and 4 months after the last dose of study therapy.

   -

Exclusion Criteria:

1. Patients with amyloidosis or central nervous system invasion or on dialysis treatment.
2. Life expectancy < 3 months.
3. History of allergy to mitoxantrone hydrochloride or liposomes；or previous treatment with adriamycin or other anthracyclines, with the total cumulative dose (doxorubicin equivalent) ≥350 mg/m^2.
4. History of allergy (except local injection reaction) or intolerance to bortezomib；or one of the following conditions occurred with prior bortezomib regimens: no treatment response (not reach MR)，disease progression within 6 months after the end of last dose.
5. History of contraindications or intolerance to dexamethasone.
6. Any anti-myeloma drug treatment or radiotherapy within 4 weeks prior to the first dose; or enrolled in any other clinical trials of anti-myeloma drug within 3 months prior to the first dose.
7. History of autologous hematopoietic stem cell transplantation within 6 months prior to screening.
8. History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
9. Adverse events from the previous treatment have not resolved to ≤ Grade 1 (except for alopecia, hyperpigmentation).
10. Patients with persistent Grade≥2 peripheral neuropathy or Grade 1 peripheral neuropathy with pain.
11. Patients with impaired cardiac function or significant cardiac disease.
12. HBsAg/HBcAb positive with HBV-DNA titer higher than the lower limit of the test value of the research center, or HCV antibody positive with HCV-RNA titer higher than the lower limit of the test value of the research center,or human immunodeficiency virus (HIV) antibody positive.
13. Patients with obvious digestive system dysfunction, which may affect intake, transport and absorption of the study drug.
14. Active bacterial, fungal or viral infections that require systemic treatment within 1 week prior to the first dose
15. Patients underwent major surgery within 6 weeks prior to the first dose, or had a surgical schedule during the study period;
16. History of additional malignant tumor within 5 years, except for locally curable cancer that has been cured.
17. Other medical conditions that, in the judgment of the investigator, may affect the patient's participation in this study.
18. Pregnant or breastfeeding women;

19. Not suitable for this study as decided by the investigator due to other reasons.

    -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 12 mg/m ^ 2 dose group (ArmA); Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2	Drug: Mitoxantrone Hydrochloride Liposome injection; Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle; Other Names: Mitoxantrone Hydrochloride Liposome; Drug: Bortezomib for Injection; Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle; Other Names: Bortezomib; Drug: Dexamethasone Acetate Tablets; Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle; Other Names: Dexamethasone
Experimental: 16 mg/m ^ 2 dose group (ArmB); Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2	Drug: Mitoxantrone Hydrochloride Liposome injection; Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle; Other Names: Mitoxantrone Hydrochloride Liposome; Drug: Bortezomib for Injection; Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle; Other Names: Bortezomib; Drug: Dexamethasone Acetate Tablets; Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle; Other Names: Dexamethasone
Experimental: 20 mg/m ^ 2 dose group (ArmC); Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2	Drug: Mitoxantrone Hydrochloride Liposome injection; Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle; Other Names: Mitoxantrone Hydrochloride Liposome; Drug: Bortezomib for Injection; Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle; Other Names: Bortezomib; Drug: Dexamethasone Acetate Tablets; Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle; Other Names: Dexamethasone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-emergent adverse events (TEAEs)	To indentify the incidence of TEAEs	From the initiation of the first dose to 28 days after the last dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR)	ORR is defined as the proportion of patients who have a best overall response of partial response (PR),very good partial response(VGPR), complete response (CR) or stringent complete response (sCR) as per International Myeloma Working Group (IMWG)	Throughout the study treatment(Up to 32 weeks)
Clinical Benefit Rate(CBR)	CBR is defined as the proportion of patients who have a best overall response of minimal response(MR),PR,VGPR,CR or sCR as per IMWG	Throughout the study treatment(Up to 32 weeks)
Disease control rate(DCR)	DCR is defined as the proportion of patients who have a best overall response of stable disease (SD),MR,PR,VGPR,CR or sCR as per IMWG	Throughout the study treatment(Up to 32 weeks)
Duration of response (DoR)	DoR is defined as the time from the first assessment of PR,VGPR,CR orsCR until the date of first occurrence of progressive disease (PD) as per IMWG	Throughout the study completion.(An average of 12 months)
Progression-free survival (PFS)	PFS is defined as the time from the date of first dose until the date of first documented PD as per IMWG or death from any cause, whichever occurs first	Throughout the study completion.(An average of 12 months)
Overall survival (OS)	OS is defined as the time from the date of first dose until the date of death from any cause	Throughout the study completion.(An average of 36 months)

Collaborators and Investigators

• Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
• Investigators: Principal Investigator: Wenming Chen, Beijing Chaoyang Hospital affiliated to Capital Medical University

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2021
• Primary Completion (Anticipated): April 20, 2023
• Study Completion (Anticipated): June 20, 2024

Study Registration Dates

• First Submitted: September 13, 2021
• First Submitted That Met QC Criteria: September 13, 2021
• First Posted (Actual): September 22, 2021

Study Record Updates

• Last Update Posted (Actual): February 1, 2022
• Last Update Submitted That Met QC Criteria: January 16, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Multiple Myeloma; Neoplasms, Plasma Cell; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Protease Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Dexamethasone; Dexamethasone acetate; BB 1101; Bortezomib; Mitoxantrone
• Other Study ID Numbers: HE071-CSP-023

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No